Taysha (TSHA) CFO offloads 102,817 shares in tax sell-to-cover

Q: How many TSHA shares did CFO Kamran Alam sell in this Form 4 filing?

According to the filing, Alam sold 78,968 shares of Taysha common stock on January 23, 2026 and 23,849 shares on January 26, 2026 , all reported as sales of non-derivative securities.

Q: At what prices were the TSHA shares sold by the CFO?

The Form 4 states that the January 23, 2026 sale was executed at a weighted average price of $4.75 per share, and the January 26, 2026 sale at a weighted average price of $4.61 per share, with actual trades occurring within the price ranges noted in the footnotes.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. chief financial officer Kamran Alam reported sales of company common stock tied to tax withholding on vested equity awards. On January 23, 2026, he sold 78,968 shares of common stock at a weighted average price of $4.75 per share. On January 26, 2026, he sold an additional 23,849 shares at a weighted average price of $4.61 per share. A footnote states these transactions were part of a mandatory sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock unit awards. After these transactions, Alam beneficially owned 1,443,786 shares of Taysha common stock directly.

Insider Trade Summary

Net Seller: 102,817 shares

Net Sell 2 txns

Insider Alam Kamran

Role CHIEF FINANCIAL OFFICER

Sold 102,817 shs ($485K)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,849	$4.61	$110K
Sale	Common Stock	78,968	$4.75	$375K

Holdings After Transaction: Common Stock — 1,443,786 shares (Direct)

Footnotes (3)

F1. The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/27/2026 - 04:05 PM

FAQ

What insider transaction did Taysha Gene Therapies (TSHA) disclose for its CFO?

Taysha Gene Therapies disclosed that its chief financial officer, Kamran Alam, sold shares of common stock in two transactions on January 23, 2026 and January 26, 2026, as reported on Form 4.

How many TSHA shares did CFO Kamran Alam sell in this Form 4 filing?

According to the filing, Alam sold 78,968 shares of Taysha common stock on January 23, 2026 and 23,849 shares on January 26, 2026, all reported as sales of non-derivative securities.

At what prices were the TSHA shares sold by the CFO?

The Form 4 states that the January 23, 2026 sale was executed at a weighted average price of $4.75 per share, and the January 26, 2026 sale at a weighted average price of $4.61 per share, with actual trades occurring within the price ranges noted in the footnotes.

Why did the Taysha Gene Therapies CFO sell TSHA shares?

A footnote explains that the CFO sold the reported shares under a mandatory sell-to-cover arrangement, solely to satisfy income tax liabilities incurred upon the vesting of restricted stock unit awards.

How many TSHA shares does the CFO own after these transactions?

Following the reported transactions, the Form 4 shows that Kamran Alam beneficially owned 1,443,786 shares of Taysha Gene Therapies common stock, held in direct ownership.

Were the TSHA insider sales executed in multiple trades?

Yes. Footnotes state that both reported transactions were executed as multiple trades, with the $4.75 and $4.61 figures reflecting weighted average prices over ranges of individual trade prices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alam Kamran

(Last)

(First)

(Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, STE 1430

(Street)

DALLAS

75247

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/23/2026		S		78,968⁽¹⁾	D	$4.75⁽²⁾	1,467,635	D
Common Stock	01/26/2026		S		23,849⁽¹⁾	D	$4.61⁽³⁾	1,443,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.

	/s/ Kamran Alam	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR